Table 3.

Published guidelines on the approach to the patient with prediabetes.

	ADA consensus statement [Nathan et al. (2007) (31)]	Indian Health Service guidelines for prediabetes [Indian Health Services (2006) (32)]	Australian Diabetes Society statement [Twigg et al. (2007) (33)]
IFG	100 ≤ FPGa < 126 mg/dL	100 ≤FPG < 126 mg/dL	110 ≤ FPG < 126 mg/dL
	5.6 ≤ FPG < 7.0 mmol/L	5.6 ≤ FPG < 7.0 mmol/L	6.1 ≤ FPG < 7.0 mmol/L
IGT	140 ≤ 2 hPG < 200 mg/dL	140 ≤ 2 hPG < 200 mg/dL	140 ≤ 2 hPG < 200 mg/dL
	7.8 ≤ 2 hPG < 11.1 mmol/L	7.8 ≤ 2 hPG < 11.1 mmol/L	7.8 ≤ 2 hPG < 11.1 mmol/L
Who should be screened for prediabetes	Individual with risk factors for diabetes	Annual testing for individuals with risk factors for diabetes	Incidental detection when screening for diabetes
Method of screening	1) FPG	1) FPG	Incidental detection when screening for diabetes
	2) 2-h OGTT if metformin is considered	2) Optional 2-h OGTT
Recommended treatment	Lifestyle modification for IFG or IGT. Lifestyle modification and/or metformin for IFG and IGT and at least 1 of the following: age <60y, BMI >35 kg/m2, family history of diabetes mellitus in first degree relative, high triglycerides, low HDL, hypertension, hemoglobin A1c >6%	Lifestyle modification	Lifestyle modification for a minimum of 6 months before pharmacotherapy
		Metformin treatment on an individualized basis
Follow-up	Metformin group: hemoglobin A1c every 6 months	Monitor glucose every 6 months	OGTT initially performed annually then retesting every 1–3 years
	Lifestyle: annual follow-up

^aFPG, fasting plasma glucose; 2 hPG, plasma glucose 2 h after a meal.